Research

Hormonal

Tirzepatide provides clinically meaningful HbA1c reduction and dose-proportional weight loss in older adults (≥65 years) with type 2 diabetes who do not have obesity (BMI < 30 kg/m2), without increasing hypoglycemic risk compared to the general population.

If you are over 65 and have type 2 diabetes but are not obese (BMI under 30), tirzepatide is a viable treatment option. It effectively lowers blood sugar and promotes weight loss without increasing the risk of dangerous low blood sugar, provided you are not already on insulin or sulfonylureas. Be aware that gastrointestinal side effects are common, but generally mild, and discontinuation rates due to side effects are slightly higher in this group than in the general population.

GoodSupportsHIGH confidence
Tirzepatide may be an effective treatment for older adults without obesity, and in this post hoc analysis, it was associated with clinically relevant HbA1c reduction and dose-proportional weight loss without increasing hypoglycemic risk.
Neda Rasouli et al. · Diabetes Therapy · 2025

Why this rating

Post hoc analysis of pooled Phase 3 randomized controlled trials (n=542 in subgroup).

Source

Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials

Neda Rasouli et al. · Diabetes Therapy · 2025

DOI 10.1007/s13300-025-01711-0

rct · n=4189Cited 6×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →